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Using the currently available proteome databases and based on the concept that a rare sequence is a potential epitope, epitopic
sequences derived from Mycobacterium tuberculosis were examined for similarity score to the proteins of the host in which the
epitopes were deﬁned. We found that: (i) most of the bacterial linear determinants had peptide fragment(s) that were rarely found
in the host proteins and (ii) the relationship between low similarity and epitope deﬁnition appears potentially applicable to T-cell
determinants. The data conﬁrmed the hypothesis that low-sequence similarity shapes or determines the epitope deﬁnition at the
molecular level and provides a potential tool for designing new approaches to prevent, diagnose, and treat tuberculosis and other
infectious diseases.
1.Introduction
Mycobacterium tuberculosis is the causative agent of tubercu-
losis (TB) and is a major infectious pathogen. A resurgence
of tuberculosis has marked the beginning of the third
millennium, with about 8 million new cases and 1.8 million
deaths annually worldwide attributed to M. tuberculosis
[1]. More recently, the World Health Organization’s Global
Tuberculosis Control Report 2009 estimated 9.27 million
cases of TB in 2007 [2], an increase from 9.24 million cases
in 2006, 8.3 million cases in 2000, and 6.6 million cases in
1990. These numbers underscore the need to develop and
characterize rational and eﬀective TB therapies and diag-
nostic reagents. Currently, the M. bovis bacillus Calmette-
Gu´ erin (BCG) vaccine is used against TB. BCG has excellent
immuno-potentiating properties, but it is not uniformly
eﬀective [3], and eﬀorts to develop a more eﬀective M. bovis-
derived vaccine against TB have not had satisfactory results
[4, 5]. Moreover, the emergence of multiple-drug-resistant
TB[6]andtheincreasingprevalenceofmycobacterialdisease
in people with acquired immunodeﬁciency syndrome [7]
add urgency to the need for an eﬀective vaccine against TB.
Recent studies have provided convincing evidence that
antibodies can protect against mycobacterial infections
[8]. Passive immunization using mono- and polyclonal
antibodies and humoral immune responses against spe-
ciﬁc mycobacterial antigens in experimental animals have
shown that antibodies may play an anti-TB role [9–11].
The epitopic characterization of mycobacterial antigens is
performed antigen-by-antigen, searching for speciﬁc pep-
tide features and epitope-paratope interaction domains for
each mycobacterial protein antigen [12–14]. In essence,
the common molecular basis and the fundamental rules
underlying the immune function of speciﬁc peptide units
remain unexplained [15, 16]. Little is known about the
structure-function relationship(s) of protein sequences in
immunology. This lack of knowledge may underlie the
confusion surrounding neutralizing versus nonneutralizing
antibodies, harmful vaccine side eﬀects, and imprecise
diagnostic tools.
Within this framework, we propose that rare peptide
sequences, that is, peptide motifs rarely found in host pro-
teins, elicit an immune response. Unique protein sequences
are more likely to evoke an immune response than are highly
repeated motifs, which would be immunogenically silenced
by tolerance. We have previously validated the relationship
between sequence rarity and peptide immunoreactivity in
cancer, autoimmunity, and infectious disease models. We2 Journal of Biomedicine and Biotechnology
reported several examples of speciﬁc targeting of peptide
regions with no or limited sequence similarity to the host
proteome, including mono- and polyclonal antibodies raised
against EC Her-2/Neu oncoprotein [17], desmoglein-3 [18],
melan-a/MART-1 [19], high-molecular-weight melanoma-
associated-antigen [20, 21], tyrosinase [22, 23], prostate-
speciﬁc-antigen [24] ,H P V 1 6E 7[ 25], HCV [26], and
inﬂuenzaA[27]proteins.Inaddition,areviewoftheepitope
mapping literature revealed that most peptide epitopes obey
thelow-similarityrule[28],furthersupportingourhypothe-
sis. Taken together, our data [17–27] and ﬁndings from other
research[28]suggestthatuniquepeptidesequencesaremore
likely to be immunogenic than are highly repeated peptide
sequences, which may be immuno-tolerated.
In the present study, we investigated the low-similarity
hypothesis in M. tuberculosis antigen epitopes with the
aim of deﬁning immunogenic peptide sequences that may
be eﬀective for anti-TB immunotherapy. We studied val-
idated M. tuberculosis epitopes currently cataloged in the
Immune Epitope Database and Analysis Resources (IEDB)
(http://www.immuneepitope.org/)[ 29, 30]. We report that
most of the mycobacterial epitopes involved in the immune
response are characterized by a low level of similarity to the
host proteome.
2. Methods
The IEDB contains hundreds of mycobacterial epitopes
derived from various strains and with diﬀerent character-
istics [30]. Speciﬁcally, the IEDB contains B- and T-cell
mycobacterial epitopes that are (a) linear or conformational;
(b) derived from M. tuberculosis, M. bovis, M. Avium,
and M. leprae; (c) of diﬀerent lengths (up to 36aa) [31];
and (d) have sequences that were negative, positive, or
produced mixed negative/positive results in immunoassays.
The present report focused on B-cell linear epitopes derived
from M. tuberculosis that were positive in immunoassays.
These mycobacterial epitopes were analyzed for sim-
ilarity to the host proteins with the aim of identifying
identicalaminoacidgroupingsthatwerecommonsequences
[32]. The amino acid groupings were linear pentapeptides.
Pentapeptides were used because the canonical literature
indicates that ﬁve to six amino acids are a suﬃcient minimal
determinant for an epitope-paratope interaction, and thus
a pentapeptide can act as an immune unit and play a
crucial role in cell immunoreactivity and antigen-antibody
recognition [33, 34].
Fifty-six M. tuberculosis epitopes cataloged as immuno-
positive at IEDB resource were dissected into pen-
tamer motifs oﬀset by one residue: that is, WDEDG,
DEDGE, EDGEK, DGEKR, and so forth. Then, each 5-
mer was used as a probe to scan the entire host pro-
teome searching for identical matches using the PIR pro-
tein database and PIR perfect peptide match program
(http://pir.georgetown.edu/pirwww/)[ 35]. The number of
matches of each mycobacterial pentamer to the host pro-
teome indicates the similarity score that can range from
no matches to hundreds of matches. Following previous
experimental data, a pentapeptide fragment that has about
ﬁve (or fewer) perfect matches to the host proteome was
considered to be a low-similarity sequence, that is, a rare
fragment [17–28].
3. Results
3.1. Low-Similarity Sequences and B-Cell Epitopes. We exam-
ined the linear M. tuberculosis-derived B-cell epitopes cat-
aloged in the IEDB [30], using pentapeptide probes as
described above and report the similarity scores (Table 1).
As shown in Table 1, most of the mycobacterial B-cell
epitopes contain pentapeptides that are rare or absent in the
host proteins. Furthermore, preliminary screening revealed
that a few B-cell epitopes were also T-cell epitopes (Table 1,
footnote 5) [36, 49–52].
The relationship between low-similarity sequences and
mycobacterial epitopes was further conﬁrmed by extend-
ing the similarity analysis to the COOH domain of the
mycobacterial DNAK protein. The DNAK chaperon protein
is a member of the highly conserved heat shock protein
family and is a protein antigen involved in the immune
response to mycobacteria [53, 54]. In particular, the DNAK
carboxy-terminus domain is highly immunogenic [41, 55]
and hosts several of the epitopes described in the IEDB
database (Table 1)[ 41]. Thus, the COOH domain of the
mycobacterial DNAK protein was suitable for verifying
the similarity-immunogenicity link. In brief, the primary
sequence of the DNAK COOH-terminus domain (aa 500–
609) was dissected into pentamers that were probed against
the human proteome by the computer-assisted similarity
analysis described in the Methods section. Then, the epitopic
sequences were allocated along the mycobacterial-versus-
human similarity proﬁle.
Figure 1 shows the similarity proﬁle of the DNAK
COOH-terminus protein to the human proteome and
the localization of the linear epitopes along the antigenic
sequence. It can be seen that the carboxy terminal sequence
of the mycobacterial chaperon protein has pentapeptides
occurring frequently in the human proteome as well as
unique fragments. Five pentamers (i.e., TWRIGY, WRIGY,
VTGHW,TGHWR,andGHWRC)wereuniquetotheDNAK
COOH-terminus domain and these accounted for 5% of the
total DNAK pentamers. The remaining 100 pentapeptides
were repeated at diﬀerent extent throughout the human
proteome and occurred a total of 2468 times. Furthermore,
and most importantly, Figure 1 shows that the peptide
epitopes recognized by the human sera, as demonstrated
by Elsaghier et al. [41], were among the mycobacterial
peptide fragments that had a low similarity to the human
proteome. That is, the unique pentapeptide signatures of
the DNAK carboxy-terminus domain coincided with the
epitopicmotifsinvolvedinimmunerecognition,indicatinga
direct relationship between low similarity and the humoural
antibody response. Conversely, M. tuberculosis peptides not
responsivetothehumanserahadahighnumberofpentamer
matches to the human proteome (Figure 1,b l a c ka r r o w s
numbered from 6 to 15).Journal of Biomedicine and Biotechnology 3
Table 1: Similarity analysis of M. tuberculosis B-cell epitopes to the host proteome.
E p i t o p eS o u r c eN a m e I E D BI D 1 Epitope Sequence2 Number of Matches3 Host Proteome4 Refs.
10 kDa chaperonin 3293 wdedGEKRIpldvae 4 H [12, 36]
10 kDa chaperonin 6508 PDTAKekpqegtvva5 3H [ 12, 36]
10 kDa chaperonin 3294 ldvaegdtvIYSKY5 2H [ 12, 36]
10 kDa chaperonin 1011756 gtvvavgpGRWDEdge5 3H [ 37–39]
10 kDa chaperonin 1011758 GRWDEdgekripldva 3 H [37–39]
10 kDa chaperonin 3290 etttasglviPDTAK5 3H [ 12, 36, 38]
10 kDa chaperonin 3289 dkilvQANEAettta 1 H [12, 36]
6k D aE S A T 5 8105 yqgvQQKWD5 1M [ 40]
6 kDa ESAT 8086 eQQWNFagieaaa5 0M [ 40]
6 kDa ESAT 8090 DEGKQsltk5 2M [ 40]
6 kDa ESAT 8106 aaAWGGSgsEAYQGvQQKWData5 3, 1, 1 M [40]
DNAK 1052559 lvyQTEKF 4 H [41]
DNAK 1052560 vyQTEKFv 4 H [41]
DNAK 1052558 yQTEKFvk 4 H [41]
DNAK 1052561 qTEKFVke 3 H [41]
DNAK 1052562 TEKFVkeq 3 H [41]
DNAK 1052583 lNKVDAav 4 H [41]
DNAK 1052584 NKVDAava 4 H [41]
DNAK 1052589 aeaEGGTW 3 H [41]
DNAK 1052591 aegGTWRI 2 H [41]
DNAK 1052593 ggTWRIGY 0 H [41]
DNAK 1052594 WRIGYfgh 0 H [41]
DNAK 1052595 riGYFGHq 2 H [41]
DNAK 1052596 igYFGHQv 1 H [41]
DNAK 1052597 GYFGHqvg 2 H [41]
DNAK 1052598 YFGHQvgd 1 H [41]
DNAK 24658 HQVGDgea 1 H [41]
DNAK 1052627 lrsSSGCV 5 H [41]
DNAK 1052628 rssSGCVT 4 H [41]
DNAK 1052629 sssGCVTG 4 H [41]
DNAK 1052630 ssgCVTGH 1 H [41]
DNAK 1052631 cvTGHWRc 0 H [41]
DNAK 1052632 VTGHWrcp 0 H [41]
DNAK 1052633 TGHWRCpp 0 H [41]
DNAK 1052549 HWRCPprr 1 H [41]
DNAK 1052550 WRCPPrrr 1 H [41]
ESAT-6-like protein ESXB 6090 laqeagNFERIsgdl5 2H [ 42]
ESAT-6-like protein ESXB 6090 laqeagNFERIsgdl 1 M [42]
Immunogenic protein MPT64 1043665 nitsATYQSaipprgtqavv 1, 0 H [43]
Immunogenic protein MPT64 1043668 hptttyKAFDWdqayrkpit 0 H [43]
Lipoprotein LPQH 1034449 vtgsvvCTTAAgnvniaigg5 2M [ 44]
Lipoprotein LPQH 1107625 vtGSVVC5 5M [ 44]
Lipoprotein LPQH 1107627 VNKSFei 1 M [44]
Lipoprotein LPQH 1052656 VKRGLtvavagaailvagls 2 M [45]
Lipoprotein LPQH 1034455 taspgaasgpkvvidGKDQN 4 M [44]
Lipoprotein LPQH 1018364 dMANPMspvnksfeievtcs 0 M [44]
MTP40 protein 1013654 gprlyGEMTMqgtrkprpsgp 2 H [46]
MTP40 protein 1011740 ttlGMHCGsfgsapsng 0 H [46]
MTP40 protein 1011751 mlgtGTPNRarINFNC 3, 3 H [46]
MTP40 protein 1011736 MLGNApsvvpnTTLGM 4, 3 H [46]
MTP40 protein 1011754 INFNCevWSNVSetisgprly 3, 2 H [46]4 Journal of Biomedicine and Biotechnology
Table 1: Continued.
E p i t o p eS o u r c eN a m e I E D BI D 1 Epitope Sequence2 Number of Matches3 Host Proteome4 Refs.
Phosphate-binding protein 1 1127065 lfnlWGPAFherypnvtita 1 M [44]
Phosphate-binding protein 1 1019382 kqdpegWGKSPgfgttvdfp 1 M [47]
Phosphate-binding protein 1 1107628 GPAFHer 1 M [44]
Phosphate-binding protein 1 1123943 gnggMVTGCaetpgcvayig 1 M [48]
Phosphate-binding protein 1 1107630 gfasKTPANqais 1 M [44]
1IEDB ID Reference Dataset of Mycobacterial Immune Epitopes: http://iedb.zendesk.com/entries/18171-reference-datasets-of-mycobacterial-immune-
epitopes.
2 Epitope sequence with amino acid sequence in one-letter code. Low-similarity pentapeptides in capital letters.
3Number of times the low-similarity pentapeptide fragment(s) occur(s) in the set of proteins that comprehensively form the host proteome (see under
Methods and [17–27]).
4H o s tp r o t e o m e :H ,h u m a n ;M ,m u r i n e .
5Sequences entirely or partially contained in M. tuberculosis T-cell epitopes [36, 49–52].
6ESAT, early secretory antigenic target.
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Figure 1: Similarity proﬁle of the mycobacterial DNAK carboxy-
terminus domain versus the human proteome at the pentapeptide
level. The columns indicate the number of DNAK pentapeptide
occurrences in the human proteome. DNAK corresponds to
hsp70 protein, UniProt accession: P0A5B9; length: 609 aa.
The numbered arrows indicate the location of mycobacterial
peptide sequences immunoassayed with human sera [41].
Black arrows refer to the immuno-negative peptide sequences
corresponding to IEDB ID: (6) 1212577 (aa FVKEQREA); (7)
1212579 (aa VKEQREAE); (8) 1212581 (aa KEQREAEG); (9)
1212582 (aa EQREAEGG); (10) 1212585 (aa QREAEGGS); (11)
1212586 (aa REAEGGSK); (12) 1212589 (aa EAEGGSKV); (13)
1212590 (aa AEGGSKVP); (14) 1212593 (aa EGGSKVPE); (15)
1212595 (aa GGSKVPED). Red arrows refer to the positive
epitopic sequences corresponding to IEDB ID: (1) 1052559; (2)
1052560; (3) 1052558; (4) 1052561; (5) 1052562; (16) 1052583;
(17) 1052584; (18) 1052589; (19) 1052591; (20) 1052593; (21)
1052594; (22) 1052595; (23) 1052596; (24) 1052597; (25) 1052598;
(26) 24658; (27) 1052627; (28) 1052628; (29) 1052629; (30)
1052630; (31) 1052631; (32) 1052632; (33) 1052633; (34) 1052549;
(35) 1052550. See Table 1 for amino acid sequence details.
IEDB ID Reference Dataset of Mycobacterial Immune Epitopes:
http://iedb.zendesk.com/entries/18171-reference-datasets-of-my-
cobacterial-immune-epitopes.
3.2. Low-Similarity Sequences and T-Cell Epitopes. The low-
similarity M. tuberculosis B-cell epitopes hosted T-cell epi-
topes [36, 49–52]i ns e v e r a lc a s e s( Table 1). These data
suggest that low-similarity inﬂuences the T- as well as the
B-cell immune response, a ﬁnding that might be used in
deﬁningT-cellepitopes.CharacterizationofT-cellepitopesis
complicated by diﬀerent sets of rules governing the immune
response. The problems include, but are not limited to,
epitope hierarchy, immunoprevalence and immunodom-
inance [56], variable epitopic length, the epitope major
histocompatibility complex (MHC) binding potential and
the diﬃculty of correctly predicting MHC binding activities
in the majority of the test-set peptides [57], and the
degenerate T-cell receptor recognition [22].
In this intricate context, the low-similarity hypothesis
may provide insight for the structural characterization of
immunogenic T-cell epitopic sequences. We know that
the optimal peptide length for MHC binding is between
nine and ﬁfteen amino acids, and the central 5-6 residues
contribute the majority of the speciﬁc contacts [59]. Thus,
as previously proposed [19], the structural features that
deﬁne an immunogenic T-cell epitope may be character-
ized by the MHC binding terminal residues ﬂanking a
central low-similarity core formed by 5-6 residues. This
m o d e li si l l u s t r a t e di nFigure 2 using an immunodominant
mycobacterial T-cell epitope validated and described by
Ivanyi et al. [58]. The immunodominant p61–80/PT19
mycobacterial epitope (VTGSVVCTTAAGNVNIAIGG) has
a critical core formed by ﬁve residues (AGNVN, aa 71–
75): a single amino acid substitution with N73A impairs
T-cell immunogenicity of the target p61–80/PT19 epi-
tope. Our similarity analysis reveals that this substitution
causes a shift in the proteomic similarity level of the ﬁve
core residues (aa 71–75) that changes from one match
(aa sequence AGNVN) to eight matches (aa sequence
AGAVN) and “hides” the 5-mer core from the immune
system.
The model illustrated in Figure 2 is supported by reports
that the HFMPT pentapeptide is a minimal antigenic deter-
minant for MHC class I-restricted T lymphocytes [60], and
theKYVKQpentapeptideisaminimalantigenicdeterminant
for CD4(+) T-cell clones [61]. Moreover, the proteomic
similarity values for HFMPT and KYVKQ were no matches
and one match, respectively.Journal of Biomedicine and Biotechnology 5
VTGSVVCTTAAGNVNIAIGG
(a)
VTGSVVCTTAAGAVNIAIGG
(b)
Figure 2: The immunogenic impact of a single amino acid substitution in the ﬁve core residues (AGNVN, aa 71–75) of the immunodom-
inant p61–80/PT19 mycobacterial epitope (VTGSVVCTTAAGNVNIAIGG). The substitution of N73A impairs T immunogenicity for the
target epitope and changes the proteomic similarity level of the ﬁve core residues (aa 71–75 underlined) from one match (aa sequence
AGNVN) to eight matches (aa sequence AGAVN). (a) The immunogenic MHC-peptide complex containing the central low-similarity
pentapeptide AGNVN (in white); (b) The nonimmunogenic MHC-peptide complex containing the higher similarity pentapeptide AGAVN
(in gray). Immunoreactivity and mutagenesis experiments are described in [58]. The ﬁgures are modiﬁed versions of the original drawings
from the website http://www.iayork.com/ by kind authorization of Professor Ian York, University of Michigan.
4. Discussion
In this study, we explored the IEDB resources to deﬁne
and characterize immunogenic mycobacterial epitopes that
could be used for eﬀective anti-TB immunotherapy. We
observed that the immunological information carried by the
M. tuberculosis antigens was localized in rare peptide frag-
ments, conﬁrming the relationship between low-similarity
and immunogenicity. Sequences containing pentapeptide
fragment(s) with low similarity to the host proteome appear
to be those involved in the humoral antibody recognition
of the mycobacterial antigen and may also inﬂuence T-cell
immunoreactivity too.
Our ﬁndings provide a method for investigating the
immune potential of the mycobacterial proteome, and thus,
may help elucidate M. tuberculosis immunobiology, one
of the primary challenges in current tuberculosis research.
This is an important issue, particularly because the epitopic
characterization of mycobacterial antigens advances slowly,
antigen-by-antigen [12–14].
Moreover, mycobacterial antigenic motifs rarely found
in host proteins are more likely to serve as potential
immunogenic antigens. Use of short peptide modules rather
than full-length mycobacterial antigens in vaccines may
increase speciﬁcity and eﬃcacy. It has been understood
since the 1980s that chemically synthesized small peptides
can induce antibodies that react with intact proteins [62].
Furthermore, peptide-based vaccines have been successfully
used against several pathologies and infectious diseases. For
example, tumour antigen-derived peptides evoked potent
antitumour immunity in the murine melanoma M-3 [63];
cytotoxic CD4+ and CD8+ T lymphocytes generated by
mutant p21-ras (12Val) peptide vaccination selectively killed
autologous tumour cells carrying this mutation [64]; Her-
2/neu peptide (aa 657–665) is an immunogenic epitope of
Her-2/neu oncoprotein with potent antitumour properties
[65]; synthetic peptides identiﬁed as antigenic sites on
the S1 subunit of pertussis toxin induced especially high
antibody titres against native pertussis toxin in mice [66]; a
linear peptide containing minimal T- and B-cell epitopes of
Plasmodium falciparum circumsporozoite protein provided
protection against a transgenic sporozoite challenge [67].
These ﬁndings indicate that the use of exact immunogenic
mycobacterial peptide sequences may provide the most
eﬀective active and passive immunotherapeutic anti-TB
approaches. In addition, a major obstacle to antibody-based
anti-TB therapy is the risk of adverse eﬀects that range from
Lupus vulgaris to granulomatous hepatitis [68–72], possibly
caused by cross-reactivity [73]. The use of low-similarity
peptides may allow the development of eﬀective vaccines
without adverse side-eﬀects [74]. In conclusion, the ﬁndings
of the present study may provide guidance in the analysis,
identiﬁcation, and utilization of the B- and T-cell response
in vaccination against mycobacterial and other infectious
diseases.
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